Rigel Pharmaceuticals | RIGL - Net Income


Rigel Pharmaceuticals reported $12.42M in Net Income for its fiscal quarter ending in September of 2024.





Net Income Change Date
Agenus USD -10.63M 74.49M Dec/2025
Amgen USD 1.82B 486M Mar/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD 30.81M 54.56M Dec/2025
AstraZeneca USD 3.08B 754M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Celldex Therapeutics USD -81.32M 14.27M Dec/2025
Daiichi Sankyo JPY 86.63B 41.32B Dec/2025
Eli Lilly USD 7.4B 760M Mar/2026
Halozyme Therapeutics USD -141.59M 316.82M Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -93M 136M Mar/2026
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
Ligand Pharmaceuticals USD 117.27M 112.43M Sep/2025
MacroGenics USD -14.16M 30.98M Dec/2025
Neurocrine Biosciences USD 153.7M 55.8M Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Veracyte USD 41.15M 22.01M Dec/2025